- Home
- TLPH vs FORA Comparison
TLPH vs FORA Comparison
Compare TLPH & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | FORA |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 69.4M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLPH | FORA |
|---|---|---|
| Price | $1.00 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 475.9K | 28.1K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $28,000.00 | ★ $28,106,911.00 |
| Revenue This Year | N/A | $51.82 |
| Revenue Next Year | N/A | $7.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $0.38 | $1.64 |
| 52 Week High | $1.57 | $4.03 |
Technical Indicators
Market Signals| Indicator | TLPH | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 46.04 |
| Support Level | $0.97 | $2.05 |
| Resistance Level | $1.07 | $2.13 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 9.37 | 47.57 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.